FINWIRES · TerminalLIVE
FINWIRES

宝辺電機の子会社が、中国XDから30%の株式と引き換えに資本注入を受ける

-- 上海証券取引所に土曜日に提出された書類によると、保定天威保辺電気(SHA:600550)の子会社である保定天威線材製造は、資本増強と2社の投資家の受け入れを計画している。 提出書類によると、中国XD電気(SHA:601179)と中国電気設備集団投資はそれぞれ1億5510万元を出資し、それぞれ30%の株式を取得する。 同社は増資の引受権を放棄したという。 今回の増資後、保辺電気の持ち株比率は100%から40%に低下する。 同社の株価は月曜日に3%下落して取引を終えた。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703